BCL9L and central nervous system cancer: We found that a stiffer matrix activated BCL9L and its downstream signals Wnt/β-catenin, whereas inhibiting Wnt/β-catenin signaling improved the anticancer effects of traditional clinical interventions, revealing a potential approach to glioma treatment (Supplementary Figure 2).